Financial Performance - For the three months ended September 30, 2025, total operating expenses were $1,873,943, a decrease of approximately 10% from $2,083,192 in the same period of 2024[97]. - The net loss for the three months ended September 30, 2025, was $1,873,669, compared to a net loss of $2,084,032 for the same period in 2024, reflecting an improvement of approximately 10%[97]. - The company incurred a loss from operations of $6,580,525 for the nine months ended September 30, 2025, contributing to an accumulated deficit of $112,652,321[104]. - Net cash used in operating activities was $6,356,680 for the nine months ended September 30, 2025, compared to $6,414,590 in 2024[108]. - Cash on hand as of September 30, 2025, was $3,757,594, which is insufficient to meet operating cash needs for the next 12 months[105]. - Management has substantial doubt about the company's ability to continue as a going concern for a period of one year from the issuance of the financial statements[106]. Expenses - General and administrative expenses increased by $235,496, or 20%, to $1,431,157 for the three months ended September 30, 2025, primarily due to higher marketing and legal expenses[98]. - General and administrative expenses decreased to $4,010,313 for the nine months ended September 30, 2025, from $4,329,565 for the same period in 2024, a decrease of 7%[101]. - Research and development expenses decreased by $400,300, or approximately 50%, to $402,417 for the three months ended September 30, 2025, driven by reduced costs in various areas[99]. - Research and development expenses increased to $2,408,839 for the nine months ended September 30, 2025, from $1,873,873 in 2024, an increase of approximately 29%[102]. - The Company experienced a significant decrease in depreciation and amortization expense, which fell by approximately 52% to $40,369 for the three months ended September 30, 2025, due to full amortization of intangible assets[100]. - Depreciation and amortization expense decreased to $161,373 for the nine months ended September 30, 2025, from $255,002 in 2024, a decrease of approximately 37%[103]. Equity and Financing - The Company reported stockholders' equity of $3,456,176 as of September 30, 2025, regaining compliance with Nasdaq Listing Rule 5550(b)(1)[95]. - The Company entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell shares of Common Stock with an aggregate offering price of up to $1,854,151, raising net cash proceeds of $1,636,799 as of September 30, 2025[91]. - Net cash provided by financing activities was $7,890,361 for the nine months ended September 30, 2025, compared to $7,210,386 in 2024[111]. - The company has not generated revenue since inception and has relied on debt and equity financing to fund operations[104]. Compliance and Risks - The Company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a stock price below $1.00 but subsequently regained compliance following a 1-for-12 reverse stock split[96]. - The company is subject to foreign currency exchange rate risk due to transactions in Canadian and Australian dollars[116]. Product Development - The Company plans to advance its lead drug candidate EB-003 through preclinical studies and aims to initiate first-in-human studies to assess safety and tolerability[88]. - The EVM401 Series was unveiled on February 25, 2025, to broaden the pipeline with additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders[90].

Revenue and Financial Performance - Revenue for Q3 2025 totaled approximately $7.3 million, with $5.1 million from XpresSpa, $1.7 million from XpresCheck, and $0.5 million from Naples Wax Center[5][13]. - Net loss attributable to XWELL for Q3 2025 was approximately $0.7 million, a significant reduction from approximately $4.8 million in the comparable prior year period[14]. - Total operating expenses for Q3 2025 were approximately $2.3 million, down from approximately $6.8 million in the prior year[13]. Cost Management - Cost of sales decreased approximately 8% from Q3 2024, totaling around $5.9 million for Q3 2025 compared to $6.4 million in the prior year[5][13]. - General and administrative expenses, excluding one-time credits, decreased approximately 32% from Q3 2024[5]. - The Company streamlined its cost structure, reducing approximately $2.4 million in annualized staffing costs[6]. Expansion and Partnerships - XWELL expanded its partnership with Priority Pass to key international airports across the Middle East and Europe, enhancing access to wellness offerings for travelers[5][7]. - New wellness centers opened in Florida, including locations at Bloomingdale Square and Waterford Lakes, with a Penn Station location set to open in mid-November[5][9]. - XWELL continues to pursue opportunities for potential acquisitions to extend its reach into the broader wellness consumer landscape[9]. Cash Position - As of September 30, 2025, the Company had approximately $4.0 million in cash and cash equivalents and no long-term debt[12].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Nevada 99-4103908 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 130 S Indian River Dr. Suite 202 pbm# 1232 Fort Pierce, FL 34950 (Add ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Registrant's telephone number, including area code: (919) 313-9633 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41827 Lite Strategy, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdicti ...

Financial Performance - For the three months ended September 30, 2025, net sales were $2,011,556, a decrease of 21% compared to $2,542,251 for the same period in 2024[18]. - Gross profit for the nine months ended September 30, 2025, was $2,860,840, down 30% from $4,086,311 in the same period of 2024[18]. - The net loss for the nine months ended September 30, 2025, was $1,943,457, compared to a net loss of $1,221,030 for the same period in 2024, indicating a deterioration of 59%[18]. - For the three months ended September 30, 2025, the company reported a net loss of $450,348, compared to a net income of $58,962 for the same period in 2024[55]. - Total revenue for the three months ended September 30, 2025, was $2,012,000, a decrease of 20.8% from $2,542,000 in the same period of 2024[63]. - For the nine months ended September 30, 2025, total revenue was $4,619,000, a decline of 30.6% from $6,670,000 in the same period of 2024[65]. Assets and Liabilities - Total current assets decreased to $5,030,309 as of September 30, 2025, from $6,493,113 at December 31, 2024, representing a decline of approximately 22%[15]. - Total liabilities increased to $5,838,709 as of September 30, 2025, compared to $5,594,799 at December 31, 2024, reflecting a rise of about 4%[15]. - Total shareholders' equity decreased to $2,206,482 as of September 30, 2025, from $4,098,939 at December 31, 2024, a decline of about 46%[15]. - Cash and cash equivalents decreased to $490,022 as of September 30, 2025, from $664,879 at December 31, 2024, a decline of approximately 26%[15]. Operating Expenses - Operating expenses for the nine months ended September 30, 2025, totaled $5,069,409, slightly up from $5,041,873 in the same period of 2024[18]. - The company’s cash paid for interest increased to $309,314 for the nine months ended September 30, 2025, compared to $222,000 for the same period in 2024, indicating higher financing costs[23]. - General and administrative expenses for the three months ended September 30, 2025, were $1,072,000, an increase of $162,000 or 18% compared to the same period in 2024[198]. Revenue Breakdown - Revenue from the SteraMist product line for the three months ended September 30, 2025, was $1,603,000, down from $1,766,000 in 2024[63]. - The company recognized service and training revenue of $409,000 for the three months ended September 30, 2025, down from $776,000 in 2024[64]. - Domestic revenue for the three months ended September 30, 2025, was $1,280,000, a decrease of $606,000 or 32% compared to the same period in 2024[188]. - International revenue for the three months ended September 30, 2025, was $732,000, an increase of $76,000 or 12% compared to the same period in 2024[189]. Cash Flow and Financing - Net cash used in operating activities was $(576,780) for the nine months ended September 30, 2025, a significant improvement compared to $(1,452,862) for the same period in 2024[23]. - Cash provided by financing activities increased significantly to $535,000 for the nine months ended September 30, 2025, compared to $28,000 in the same period of 2024[211]. - The company plans to fund ongoing activities through current cash, cash generated from operations, and raising additional capital, though there is no assurance of success in raising such capital[85]. Inventory and Credit Losses - The allowance for credit losses increased to $2,229,977 as of September 30, 2025, up from $1,494,347 at December 31, 2024, indicating a rise in expected credit losses[39]. - The reserve for obsolete inventory was $868,000 as of September 30, 2025, down from $1,100,000 as of December 31, 2024, indicating improved inventory management[43]. - The company reported a credit loss expense of $197,639 for the nine months ended September 30, 2025, compared to $1,050,543 for the same period in 2024, showing a decrease in credit loss expense[39]. Strategic Initiatives - The company successfully completed multiple high-profile installations of its iHP technology, including at NASA's Johnson Space Center and Virginia Commonwealth University, demonstrating its adaptability in high-containment environments[152]. - The FDA's final rule broadening the use of hydrogen peroxide as a direct food additive is expected to positively impact the company's positioning in the food safety market, particularly in the ready-to-eat segment[157]. - The company is experiencing revenue growth among distributors and international partners, particularly in Europe, as it works towards finalizing regulatory approvals in the EU and UK[155]. Management and Governance - The company appointed a new Chief Financial Officer with an annual base salary of $230,000 and eligibility for a bonus of up to 40% of the base salary[122]. - Management is implementing measures to improve financial results and cash flows, including optimizing product mix and expanding recurring solution sales, to support liquidity needs through 2025[212].

Financial Performance - The company reported net losses of approximately $15.8 million and $8.9 million for the years ended December 31, 2024 and 2023, respectively, and $11.4 million and $7.7 million for the nine months ended September 30, 2025 and 2024, respectively [51]. - The company incurred net losses of $11,435,485 and $7,748,590 during the nine-month periods ended September 30, 2025 and 2024, respectively [59]. Expenses - Research and development expenses increased by $1,229,536 or 54%, to $3,521,576 for the three months ended September 30, 2025, compared to $2,292,040 for the same period in 2024 [53]. - General and administrative expenses rose by $216,055, or 49%, to $653,066 for the three months ended September 30, 2025, from $437,011 for the same period in 2024 [54]. - For the nine months ended September 30, 2025, research and development expenses increased by $2,836,178, or 42%, to $9,630,604 from $6,794,426 for the same period in 2024 [55]. - General and administrative expenses for the nine months ended September 30, 2025, increased by $739,093, or 65%, to $1,872,323 from $1,133,230 for the same period in 2024 [56]. Cash Position - As of September 30, 2025, the company's cash totaled $3,806,978, down from $4,091,990 as of December 31, 2024 [58]. - Net cash used in operating activities was $6,738,796 for the nine months ended September 30, 2025, compared to $5,414,337 for the same period in 2024 [60]. Capital Raising - The company completed At The Market ("ATM") offerings resulting in gross proceeds of $6,492,994 from the issuance of 621,674 shares at an average price of $10.44 per share between January 1, 2025, and September 30, 2025 [64]. Clinical Trials - The company plans to expand its Phase III clinical trial, Flamingo-01, into Europe with plans to open up to 150 sites globally [50].

ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | | Page | | --- | --- | | Condensed Consolidated Balance Shee ...

Revenue Performance - Revenue increased by 128% year over year to $1.8 million for the fiscal quarter ended September 30, 2025, compared to $0.8 million for the same period last year[8] - Revenues for the three months ended September 30, 2025, were $1,818,000, compared to $798,000 for the same period in 2024, representing a 128% increase[32] - Updated fiscal year 2026 revenue guidance to $8 - $10 million[19] Expenses and Losses - Gross loss decreased to $0.3 million for the quarter ended September 30, 2025, compared to a gross loss of $1.1 million for the same period last year[11] - Research and development expenses decreased to $2.5 million for the quarter ended September 30, 2025, from $4.6 million for the same period last year[12] - Selling, general and administrative expenses decreased to $4.9 million for the quarter ended September 30, 2025, compared to $7.2 million for the same period last year[13] - Net loss attributed to common stockholders was ($7.9) million or a loss of ($1.25) per share for the quarter ended September 30, 2025, compared to a net loss of ($13.4) million or ($5.67) per share for the same period last year[15] - The net loss attributable to Beyond Air, Inc. for the three months ended September 30, 2025, was $7,940,000, compared to $13,358,000 for the same period in 2024, reflecting a 41% decrease[32] Cash and Assets - Proforma cash, cash equivalents, restricted cash, and marketable securities totaled $22.9 million as of September 30, 2025[1] - Cash and cash equivalents increased to $9,699,000 as of September 30, 2025, from $4,665,000 as of March 31, 2025[33] - Total assets as of September 30, 2025, were $30,965,000, compared to $30,062,000 as of March 31, 2025, showing a growth of 3%[33] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $7,363,000, down from $11,748,000 in the same period of 2024, indicating a 37% reduction[32] - Research and development expenses for the six months ended September 30, 2025, were $5,536,000, down from $10,594,000 in the same period of 2024, a reduction of 48%[32] Distribution and Designation - The company expanded its global LungFit PH distribution network to 35 countries, covering a combined population of 2.8 billion people[8] - The U.S. FDA granted Orphan Drug Designation to investigational therapies BA-101 and BA-102 for the treatment of Glioblastoma and Phelan-McDermid Syndrome, respectively[16] Other Financial Metrics - Net cash burn for the quarter ended September 30, 2025, was $4.7 million[17] - The weighted average number of shares outstanding for the three months ended September 30, 2025, was 6,356,573, compared to 2,355,927 for the same period in 2024, indicating a significant increase in shares[32] - The total liabilities as of September 30, 2025, were $17,870,000, an increase from $15,721,000 as of March 31, 2025[33] - The company reported a foreign currency translation loss of $18,000 for the three months ended September 30, 2025[32]